BRPI0715989A8 - "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" - Google Patents

"seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"

Info

Publication number: BRPI0715989A8
Authority: BR; Brazil
Prior art keywords: antibodies; antibody; composition; sequences; chain
Prior art date: 2006-10-19

Application number

BRPI0715989A

Other languages

English (en)

Inventor

Stephen Zhou Bin-Bing

Li Kang

Singh Sanjaya

Chung Fung Sek

Wu Wenjuan

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-19

Filing date

2007-10-18

Publication date

2018-03-13

2007-10-18 Application filed by Genentech Inc filed Critical Genentech Inc

2014-03-18 Publication of BRPI0715989A2 publication Critical patent/BRPI0715989A2/pt

2018-03-13 Publication of BRPI0715989A8 publication Critical patent/BRPI0715989A8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Diabetes (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Mycology (AREA)
Epidemiology (AREA)

BRPI0715989A 2006-10-19 2007-10-18 "seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição" BRPI0715989A8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US85286106P	2006-10-19	2006-10-19
US87921807P	2007-01-06	2007-01-06
PCT/US2007/081797 WO2008051797A2 (en)	2006-10-19	2007-10-18	Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases

Publications (2)

Publication Number	Publication Date
BRPI0715989A2 BRPI0715989A2 (pt)	2014-03-18
BRPI0715989A8 true BRPI0715989A8 (pt)	2018-03-13

Family

ID=39325263

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0715989A BRPI0715989A8 (pt)	2006-10-19	2007-10-18	"seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmentos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"

Country Status (19)

Country	Link
US (5)	US7915390B2 (pt)
EP (1)	EP2087006B1 (pt)
JP (1)	JP5478254B2 (pt)
KR (2)	KR101525629B1 (pt)
AR (1)	AR063494A1 (pt)
AU (1)	AU2007309229B8 (pt)
BR (1)	BRPI0715989A8 (pt)
CA (1)	CA2666672A1 (pt)
CL (1)	CL2007002987A1 (pt)
CO (1)	CO6180445A2 (pt)
CR (1)	CR10730A (pt)
MA (1)	MA30900B1 (pt)
MX (1)	MX2009004106A (pt)
NO (1)	NO20091926L (pt)
PE (1)	PE20081264A1 (pt)
PH (1)	PH12015500576A1 (pt)
RU (1)	RU2461569C2 (pt)
TW (1)	TW200824707A (pt)
WO (1)	WO2008051797A2 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6984522B2 (en)	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
WO2005111072A2 (en) *	2004-04-29	2005-11-24	The Trustees Of Columbia University In The City Of New York	Notch-based fusion proteins and uses thereof
WO2008057144A2 (en) *	2006-05-15	2008-05-15	The Brigham And Women's Hospital, Inc.	Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
WO2007145840A2 (en)	2006-06-13	2007-12-21	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
CL2007002987A1 (es)	2006-10-19	2008-06-06	Genentech Inc	Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3.
UA102061C2 (ru)	2006-10-19	2013-06-10	Дженентек, Інк.	Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
RU2493167C2 (ru)	2006-12-18	2013-09-20	Дженентек, Инк.	АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ
AU2008209482B2 (en)	2007-01-24	2014-05-01	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
WO2008092002A2 (en)	2007-01-24	2008-07-31	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing pancreatic cancer
US20090208491A1 (en) *	2007-02-14	2009-08-20	Austin Gurney	Compositions and Methods for Diagnosing and Treating Cancer
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
RU2532830C2 (ru)	2007-08-23	2014-11-10	Дзе Трастиз Оф Коламбия Юниверсити Ин Дзе Сити Оф Нью Йорк	Композиции гуманизированных слитых белков notch и способы лечения
US9132189B2 (en)	2008-07-08	2015-09-15	Oncomed Pharmaceuticals, Inc.	Notch1 binding agents and methods of use thereof
CA2729602A1 (en)	2008-07-08	2010-01-14	Oncomed Pharmaceuticals, Inc.	Notch1 receptor binding agents and methods of use thereof
JP2012500791A (ja) *	2008-08-22	2012-01-12	ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク	Ｎｏｔｃｈ３シグナル伝達のデコイインヒビターとしてのヒトｎｏｔｃｈ３に基づく融合タンパク質
AR073717A1 (es) *	2008-10-01	2010-11-24	Genentech Inc	Anticuerpos anti-notch2 de murino y humano, y metodos de uso
WO2010141249A2 (en) *	2009-06-02	2010-12-09	Merck Sharp & Dohme Corp.	Generation, characterization and uses thereof of anti-notch3 antibodies
JP5113812B2 (ja) *	2009-08-31	2013-01-09	清中川	コロニーピッキング装置、コロニーピッキング方法、及び融合細胞クローン作製方法
PH12012500574A1 (en)	2009-09-30	2012-10-22	Genentech Inc	Notch1-antagonist-resistant cancer(s) using notch3 antagonists
WO2011088215A2 (en)	2010-01-13	2011-07-21	Oncomed Pharmaceuticals, Inc.	Notch1 binding agents and methods of use thereof
US20130095493A1 (en) *	2011-10-03	2013-04-18	The Johns Hopkins University	Identification of the gene notch3 as a novel biomarker for human metastatic melanoma
TW201329105A (zh)	2011-10-04	2013-07-16	Thr Trustees Of Columbia University In The City Of New York	人類ｎｏｔｃｈ１引誘物
US20150140043A1 (en) *	2012-05-10	2015-05-21	Institut National De La Sante De La Recherche Medical (Inserm)	Immunomodulatory methods using notch agonists
CA2890571A1 (en) *	2012-11-07	2014-05-15	Kenneth G. Geles	Anti-notch3 antibodies and antibody-drug conjugates
US9879083B2 (en) *	2012-12-19	2018-01-30	Aveo Pharmaceuticals, Inc.	Anti-Notch3 antibodies
US9683039B2 (en) *	2013-03-14	2017-06-20	New York University	Notch agonists for the treatment of cancer
JP2016514130A (ja)	2013-03-14	2016-05-19	ノバルティスアーゲー	Ｎｏｔｃｈ３に対する抗体
JP6641299B2 (ja) *	2014-06-04	2020-02-05	フレッドハッチンソンキャンサーリサーチセンター	Ｎｏｔｃｈ１および／またはＮｏｔｃｈ２アゴニストを用いた幹細胞の増殖および生着
BR112017000130A2 (pt)	2014-07-11	2018-01-09	Genentech Inc	método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer
JP6912375B2 (ja) *	2014-09-25	2021-08-04	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	皮質下梗塞及び白質脳症を伴う常染色体優性脳動脈症の免疫学的処置
WO2017172260A1 (en)	2016-03-31	2017-10-05	Ngm Bioparmaceuticals, Inc.	Binding proteins and methods of use thereof
WO2017190025A1 (en) *	2016-04-29	2017-11-02	Aveo Pharmaceuticals, Inc.	Anti-notch3 antibody
US20200103419A1 (en)	2017-03-27	2020-04-02	The Schepens Eye Research Institute, Inc.	Blood biomarkers and diagnostic methods for small vessel diseases
WO2018183216A1 (en)	2017-03-27	2018-10-04	The Schepens Eye Research Institute, Inc.	Notch3 agonist compositions and methods for treating small vessel diseases
US11325969B2 (en) *	2017-08-29	2022-05-10	Veritas Therapeutics Inc.	FGL2 antibodies and binding fragments thereof and uses thereof
BR112021003830A2 (pt)	2018-08-28	2021-07-20	Fred Hutchinson Cancer Research Center	métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
US12269874B2 (en) *	2018-12-03	2025-04-08	mAbProtein Co., Ltd.	Antibody that recognizes neoepitope of activated interleukin-18 proteins and application thereof
CN115943163A (zh) *	2020-06-30	2023-04-07	中外制药株式会社	位点特异性Notch激活分子及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE20030749A1 (en) *	1991-05-03	2003-11-12	Indiana University Foundation	Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5786158A (en) *	1992-04-30	1998-07-28	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) *	1992-04-30	2005-05-26	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
JPH09506262A (ja)	1993-12-08	1997-06-24	ジェンザイム・コーポレイション	特異的抗体の製造方法
US20050158859A1 (en) *	1995-09-29	2005-07-21	Yale University	Manipulation of non-terminally differentiated cells using the Notch pathway
US5780300A (en) *	1995-09-29	1998-07-14	Yale University	Manipulation of non-terminally differentiated cells using the notch pathway
FR2751986B1 (fr) *	1996-08-01	1998-12-31	Inst Nat Sante Rech Med	Gene implique dans le cadasil, methode de diagnostic et application therapeutique
US6436650B1 (en) *	1997-07-23	2002-08-20	Yale University	Activated forms of notch and methods based thereon
US6692919B1 (en) *	1997-07-23	2004-02-17	Yale University	Activated forms of notch and methods based thereon
FR2777285B1 (fr)	1998-04-10	2000-05-19	Bio Merieux	Ligand peptidique presentant une affinite specifique vis-a-vis de la proteine p24 du retrovirus hiv-1
WO2000020576A2 (en)	1998-10-02	2000-04-13	The Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health	Methods and compositions for inducing differentiation and apotosis in cells that overexpess the notch protein
US8084258B2 (en) *	1999-07-12	2011-12-27	University Of Basel	Manipulation of tissue of organ type using the notch pathway
US20020151487A1 (en) *	2000-08-31	2002-10-17	Loyola University Chicago	Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
CA2422538C (en)	2000-09-22	2012-06-19	Genentech, Inc.	Notch receptor agonists and uses
AU2003255735A1 (en) *	2002-08-03	2004-02-23	Lorantis Limited	Conjugate of notch signalling pathway modulators and their use in medical treatment
US7837993B2 (en)	2004-03-19	2010-11-23	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for regeneration of aged skeletal muscle tissues
US20080287309A1 (en)	2004-07-10	2008-11-20	Alexion Pharmaceuticals, Inc.	Methods for Discovering Antibodies Specific to Cancer Cells and Antibodies Discovered Thereby
US20070077245A1 (en)	2004-08-04	2007-04-05	The Brigham And Women's Hospital, Inc.	NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en)	2004-11-05	2006-05-18	The Regents Of The University Of California	Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en)	2004-12-20	2006-06-29	Genentech, Inc.	Notch receptor agonists and uses
DK1962895T3 (da) *	2005-12-16	2013-03-04	Regeneron Pharma	TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
WO2008057144A2 (en)	2006-05-15	2008-05-15	The Brigham And Women's Hospital, Inc.	Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
CL2007002987A1 (es) *	2006-10-19	2008-06-06	Genentech Inc	Anticuerpos anti-notch3; acido nucleico que los codifica; vector y celula que lo comprende; metodo de produccion; y su uso para tratar enfermedades relacionadas con notch3.
UA102061C2 (ru)	2006-10-19	2013-06-10	Дженентек, Інк.	Агонистическое антитело к notch3 и его применение для лечения notch3- ассоциированных заболеваний
RU2493167C2 (ru)	2006-12-18	2013-09-20	Дженентек, Инк.	АНТИТЕЛА-АНТАГОНИСТЫ ПРОТИВ Notch3 И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С Notch3 ЗАБОЛЕВАНИЙ
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica

2007
- 2007-10-18 CL CL200702987A patent/CL2007002987A1/es unknown
- 2007-10-18 AR ARP070104625A patent/AR063494A1/es unknown
- 2007-10-18 PE PE2007001412A patent/PE20081264A1/es not_active Application Discontinuation
- 2007-10-18 RU RU2009118621/10A patent/RU2461569C2/ru not_active IP Right Cessation
- 2007-10-18 TW TW096139048A patent/TW200824707A/zh unknown
- 2007-10-18 WO PCT/US2007/081797 patent/WO2008051797A2/en not_active Ceased
- 2007-10-18 KR KR1020097010122A patent/KR101525629B1/ko not_active Expired - Fee Related
- 2007-10-18 EP EP07844405.6A patent/EP2087006B1/en active Active
- 2007-10-18 MX MX2009004106A patent/MX2009004106A/es active IP Right Grant
- 2007-10-18 KR KR1020157004016A patent/KR20150023953A/ko not_active Ceased
- 2007-10-18 US US11/874,682 patent/US7915390B2/en active Active
- 2007-10-18 CA CA002666672A patent/CA2666672A1/en not_active Abandoned
- 2007-10-18 JP JP2009533527A patent/JP5478254B2/ja not_active Expired - Fee Related
- 2007-10-18 AU AU2007309229A patent/AU2007309229B8/en not_active Ceased
- 2007-10-18 BR BRPI0715989A patent/BRPI0715989A8/pt not_active IP Right Cessation
- 2007-10-18 US US11/874,645 patent/US7994285B2/en not_active Expired - Fee Related
2009
- 2009-04-17 CR CR10730A patent/CR10730A/es not_active Application Discontinuation
- 2009-05-14 MA MA31887A patent/MA30900B1/fr unknown
- 2009-05-18 NO NO20091926A patent/NO20091926L/no not_active Application Discontinuation
- 2009-05-18 CO CO09050698A patent/CO6180445A2/es active IP Right Grant
2011
- 2011-02-23 US US13/033,500 patent/US8187839B2/en active Active
2012
- 2012-04-23 US US13/453,817 patent/US20120213785A1/en not_active Abandoned
2013
- 2013-08-21 US US13/972,443 patent/US9518124B2/en not_active Expired - Fee Related
2015
- 2015-03-17 PH PH12015500576A patent/PH12015500576A1/en unknown

Also Published As

Publication number	Publication date
AU2007309229A2 (en)	2009-05-28
WO2008051797A2 (en)	2008-05-02
US20080131908A1 (en)	2008-06-05
US7915390B2 (en)	2011-03-29
AU2007309229B2 (en)	2013-01-10
TW200824707A (en)	2008-06-16
US20080118520A1 (en)	2008-05-22
US20140093889A1 (en)	2014-04-03
US20120213785A1 (en)	2012-08-23
BRPI0715989A2 (pt)	2014-03-18
EP2087006A2 (en)	2009-08-12
PE20081264A1 (es)	2008-10-01
CA2666672A1 (en)	2008-05-02
CL2007002987A1 (es)	2008-06-06
CR10730A (es)	2009-06-19
US7994285B2 (en)	2011-08-09
AU2007309229B8 (en)	2013-05-09
NO20091926L (no)	2009-07-17
MX2009004106A (es)	2009-04-28
KR101525629B1 (ko)	2015-06-26
JP2010506596A (ja)	2010-03-04
KR20090080979A (ko)	2009-07-27
US20100111971A9 (en)	2010-05-06
RU2461569C2 (ru)	2012-09-20
AU2007309229A1 (en)	2008-05-02
RU2009118621A (ru)	2010-11-27
EP2087006B1 (en)	2016-06-08
MA30900B1 (fr)	2009-11-02
US9518124B2 (en)	2016-12-13
JP5478254B2 (ja)	2014-04-23
AR063494A1 (es)	2009-01-28
CO6180445A2 (es)	2010-07-19
US20110206675A1 (en)	2011-08-25
PH12015500576A1 (en)	2016-07-25
KR20150023953A (ko)	2015-03-05
US8187839B2 (en)	2012-05-29
WO2008051797A3 (en)	2008-07-31

Legal Events

Date	Code	Title	Description
2018-03-13	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-08-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 12A ANUIDADE.
2019-12-03	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2536 DE 13-08-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
WO2021156490A3 (en)	2021-09-16	Corona virus binders
NZ595235A (en)	2013-06-28	Compositions and methods for increasing muscle growth
EA201200526A1 (ru)	2012-11-30	Поливалентные антитела, стабилизированные дисульфидом
NZ602780A (en)	2014-04-30	Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
BRPI0715989A2 (pt)	2014-03-18	"seqüencia variável da cadeia pesada ("vh"), região da cadeia vh, seqüências variável da cadeia leve ("vl"), região da cadeia vl, seqüencias da cadeia vh, ácidos nucléicos, vetor, célula, anticorpos ou fragmebtos anticorpos, anticorpos, método para a produção de anticorpo, uso de um anticorpo, epítopos de ligação do notch3, composição e uso da composição"
WO2012027721A3 (en)	2012-08-16	Antibodies to matrix metalloproteinase 9
NZ587198A (en)	2012-10-26	Monoclonal antibodies against the rgm a protein and uses thereof
EA201101593A1 (ru)	2012-06-29	КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
WO2008079995A3 (en)	2008-08-28	Conjugate of natriuretic peptide and antibody constant region
HK1204981A1 (en)	2015-12-11	Antibodies to matrix metalloproteinase 9
WO2010115589A8 (en)	2011-10-27	Trivalent, bispecific antibodies
AR072897A1 (es)	2010-09-29	Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
WO2009068649A3 (en)	2010-02-04	Antigen-binding constructs
WO2008079246A3 (en)	2009-01-08	Cd44 antibodies
WO2013043933A3 (en)	2013-05-30	Cd27l antigen binding proteins
CO6180467A2 (es)	2010-07-19	Moleculas de anticuerpo que unen il -17 e il- 17 f
WO2002096948A3 (en)	2003-08-07	Engineered tetravalent antibodies and methods of use
WO2008070344A3 (en)	2008-11-20	Compositions and methods for binding sphingosine-1-phosphate
WO2009071696A3 (en)	2009-09-03	Humanized antibody molecules specific for il-31
PY0227624A (es)	2004-06-01	Anticuerpos para el antígeno cd40
WO2009112245A9 (en)	2009-11-05	Antibody against the csf-1 r
PE20201171A1 (es)	2020-10-28	Anticuerpos de cadena pesada que se unen a cd22
BRPI0818437A2 (pt)	2015-05-12	Anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menosum dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
CL2010000096A1 (es)	2010-06-25	Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06).
WO2008134724A3 (en)	2009-02-12	Methods for administering anti-il-5 antibodies